Jazz Pharmaceuticals Announces That Patient Enrollment is Complete for the Phase 3 Study of JZP-110 Evaluating Excessive Sleepiness in Narcolepsy by mparnell | Nov 28, 2016 | Portfolio News
Aimmune Therapeutics Completes Global Enrollment of Phase 3 PALISADE Trial of AR101 for the Treatment of Peanut Allergy by mparnell | Nov 28, 2016 | Portfolio News
Aimmune Therapeutics Closes $145 Million Investment by Nestlé Health Science by mparnell | Nov 28, 2016 | Portfolio News
Independent Review of Xtampza® ER Published in Peer-Reviewed Medical Journal by mparnell | Nov 21, 2016 | Portfolio News
Aimmune Therapeutics Announces Third Quarter 2016 Financial Results and Provides Corporate Update by mparnell | Nov 14, 2016 | Portfolio News
